Cart
BCG Vaccines Sales Market by Drug Type (Immune BCG and Therapy BCG), Usage (Tuberculosis and Bladder Cancer), and End User (Pediatrics and Adults): Opportunity Analysis and Industry Forecast, 2018 - 2025
|
LI_182604
|
Pages: 119
|
Apr
2019 |
2271 Views
|
|
|
|
Author(s) :
Ravi Telugunta & Onkar Sumant
|
Tables: 89
|
Charts: 09
|
Formats*:
|
|
Bcg Vaccines Sales Market Outlook - 2025
The global BCG vaccines sales market was valued at $45 million in 2017, and is estimated to reach $65 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025.Bacillus Calmette‐Guérin (BCG) vaccine is the only vaccine available for the prevention of tuberculosis (TB). This vaccine is generally administered to children at birth in countries with high incidence of TB. However, in low incidence regions, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.
Get more information on this report : Request Sample Pages
The global BCG vaccines sales market is driven by increase in the prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, increase in government initiatives and focus on immunization programs globally boost the market growth. However, side-effects and a global shortage of BCG vaccine restrain the BCG vaccines sales market growth. Furthermore, untapped market potential in developing regions is expected to provide lucrative opportunities for BCG vaccines sales market size.
Global Bcg Vaccines Sales Market Segmentation
The global BCG vaccines sales market is based on the segments such as drug type, usage, end user, and region. Based on drug type, it is bifurcated into immune BCG and therapy BCG. Based on usage, the market is categorized into tuberculosis and bladder cancer. Based on end user, it is segmented into adults and pediatrics. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Get more information on this report : Request Sample Pages
Segment review
According to drug type, the immune BCG segment accounted for the highest share in 2017 and is also the fastest growing segment growing at a CAGR of 4.9% during the BCG vaccines sales market forecast period. The factors contributing toward the growth of this segment include the role of BCG in effectively helping TB prevention and as of now there is no substitute vaccine for immune BCG.
Get more information on this report : Request Sample Pages
By usage, the tuberculosis segment accounted for the highest share in 2017 and is also the fastest growing segment growing at a CAGR of 5.0% during the forecast period. The growth was attributed to high prevalence of tuberculosis and increase in number of drug resistant infections. Moreover, BCG vaccine is most commonly administered to the newborn and young children to prevent them from tuberculosis.
Get more information on this report : Request Sample Pages
Key Benefits for Bcg Vaccines Sales Market:
- This report entails BCG vaccines sales market analysis along with the current global BCG vaccines sales market trends from 2017 to 2025 to identify the prevailing opportunities along with the strategic assessment.
- The global BCG vaccines sales market forecast is studied from 2018 to 2025.
- The global BCG vaccines sales market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
Bcg Vaccines Sales Key Market Segments:
By Drug Type
- Immune BCG
- Therapy BCG
By Usage
- Tuberculosis
- Bladder Cancer
By End User
- Pediatrics
- Adults
By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East
- Africa
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Market dynamics
3.3.1. Drivers
3.3.1.1. High prevalence of tuberculosis worldwide
3.3.1.2. Rise in number of drug-resistant tuberculosis cases
3.3.2. Opportunity
3.3.2.1. Initiatives by United Nations (UN) for TB prevention worldwide
3.3.3. Challenge
3.3.3.1. Replacement for BCG vaccine
CHAPTER 4: BCG VACCINE SALES MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Immune BCG
4.2.1. Key market trends, growth factors, and opportunities
4.3. Therapy BCG
4.3.1. Key market trends, growth factors, and opportunities
CHAPTER 5: BCG VACCINE SALES MARKET, BY USAGE
5.1. Overview
5.1.1. Market size and forecast
5.2. Tuberculosis
5.2.1. Key market trends, growth factors, and opportunities
5.3. Bladder Cancer
5.3.1. Key market trends, growth factors, and opportunities
CHAPTER 6: GLOBAL BCG VACCINES SALES MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pediatrics
6.2.1. Key market trends, growth factors, and opportunities
6.3. Adults
6.3.1. Key market trends, growth factors, and opportunities
CHAPTER 7: BCG VACCINES SALES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key growth factors and opportunities
7.2.2. Market size and forecast, by drug type
7.2.3. Market size and forecast, by usage
7.2.4. Market size and forecast, by end user
7.2.5. Market size and forecast, by country
7.2.5.1. U.S. market size and forecast, by drug type
7.2.5.2. U.S. market size and forecast, by usage
7.2.5.3. U.S. market size and forecast, by end user
7.2.5.4. Canada market size and forecast, by drug type
7.2.5.5. Canada market size and forecast, by usage
7.2.5.6. Canada market size and forecast, by end user
7.2.5.7. Mexico market size and forecast, by drug type
7.2.5.8. Mexico market size and forecast, by usage
7.2.5.9. Mexico market size and forecast, by end user
7.2.5.10. Europe
7.2.6. Key market trends growth factors and opportunities
7.2.7. Market size and forecast, by drug type
7.2.8. Market size and forecast, by usage
7.2.9. Market size and forecast, by end user
7.2.10. Market size and forecast, by country
7.2.10.1. Germany market size and forecast, by drug type
7.2.10.2. Germany market size and forecast, by usage
7.2.10.3. Germany market size and forecast, by end user
7.2.10.4. France market size and forecast, by drug type
7.2.10.5. France market size and forecast, by usage
7.2.10.6. France market size and forecast, by end user
7.2.10.7. UK market size and forecast, by drug type
7.2.10.8. UK market size and forecast, by usage
7.2.10.9. UK market size and forecast, by end user
7.2.10.10.Italy market size and forecast, by drug type
7.2.10.11.Italy market size and forecast, by usage
7.2.10.12.Italy market size and forecast, by end user
7.2.10.13.Spain market size and forecast, by drug type
7.2.10.14.Spain market size and forecast, by usage
7.2.10.15.Spain market size and forecast, by end user
7.2.10.16. Rest of Europe market size and forecast, by drug type
7.2.10.17.Rest of Europe market size and forecast, by usage
7.2.10.18.Rest of Europe market size and forecast, by end user
7.3. Asia-Pacific
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by drug type
7.3.3. Market size and forecast, by usage
7.3.4. Market size and forecast, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. Japan market size and forecast, by drug type
7.3.5.2. Japan market size and forecast, by usage
7.3.5.3. Japan market size and forecast, by end user
7.3.5.4. China market size and forecast, by drug type
7.3.5.5. China market size and forecast, by usage
7.3.5.6. China market size and forecast, by end user
7.3.5.7. India market size and forecast, by drug type
7.3.5.8. India market size and forecast, by usage
7.3.5.9. India market size and forecast, by end user
7.3.5.10. Rest of Asia-Pacific market size and forecast, by drug type
7.3.5.11. Rest of Asia-Pacific market size and forecast, by usage
7.3.5.12. Rest of Asia-Pacific market size and forecast, by end user
7.4. LAMEA
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by drug type
7.4.3. Market size and forecast, by usage
7.4.3.1. LAMEA market size and forecast, by end user
7.4.4. Market size and forecast, by country
7.4.4.1. Latin America market size and forecast, by drug type
7.4.4.2. Latin America market size and forecast, by usage
7.4.4.3. Latin America market size and forecast, by end user
7.4.4.4. Middle East market size and forecast, by drug type
7.4.4.5. Middle East market size and forecast, by usage
7.4.4.6. Middle East market size and forecast, by end user
7.4.4.7. Africa market size and forecast, by drug type
7.4.4.8. Africa market size and forecast, by usage
7.4.4.9. Africa market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. AJ Vaccines
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.2. China National Pharmaceutical Group Corporation (Sinopharm)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.3. GREENSIGNAL BIO PHARMA LIMITED
8.3.1. Company overview
8.3.2. GSBPL: company snapshot
8.3.3. Operating business segments
8.3.4. Key strategic moves and development
8.3.5. Product portfolio
8.4. INTERVAX LTD
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. JAPAN BCG LABORATORY
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. MERCK & COMPANY INC
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. SANOFI S.A.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. SERUM INSTITUTE OF INDIA PVT. LTD
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments
8.9. STATENS SERUM INSTITUTE
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL BCG VACCINES SALES MARKET, BY DRUG TYPE 2017-2025, ($MILLION)
TABLE 02. GLOBAL BCG VACCINES SALES MARKET, BY USAGE 2017-2025, ($MILLION)
TABLE 03. GLOBAL BCG VACCINES SALES MARKET, BY USAGE 2017-2025, ($MILLION)
TABLE 04. BCG VACCINES SALES MARKET, BY REGION 2017-2025, ($MILLION)
TABLE 05. NORTH AMERICA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 06. NORTH AMERICA VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 07. NORTH AMERICA VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 08. NORTH AMERICA BCG VACCINES SALES MARKET, BY COUNTRY, 2017-2025, ($MILLION)
TABLE 09. MEXICO BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 10. U.S. VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 11. U.S. BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 12. CANADA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 13. CANADA VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 14. CANADA BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 15. MEXICO BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 16. MEXICO VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 17. MEXICO BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 18. EUROPE BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 19. EUROPE VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 20. EUROPE VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 21. EUROPE BCG VACCINES SALES MARKET, BY COUNTRY, 2017-2025, ($MILLION)
TABLE 22. GERMANY BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 23. GERMANY VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 24. GERMANY BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 25. FRANCE BCG VACCINES SALES MARKET, BY DRUG TYPE 2017-2025, ($MILLION)
TABLE 26. FRANCE BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 27. FRANCE BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 28. UK BCG VACCINES SALES MARKET, BY DRUG TYPE 2017-2025, ($MILLION)
TABLE 29. UK BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION) 58
TABLE 30. UK BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 31. ITALY BCG VACCINES SALES MARKET, BY DRUG TYPE 2017-2025, ($MILLION)
TABLE 32. ITALY BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 33. ITALY BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 34. SPAIN BCG VACCINES SALES MARKET, BY DRUG TYPE 2017-2025, ($MILLION)
TABLE 35. SPAIN BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 36. SPAIN BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 37. REST OF EUROPE BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 38. REST OF EUROPE BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 39. REST OF EUROPE BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 40. ASIA-PACIFIC BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 41. ASIA-PACIFIC VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 42. ASIA-PACIFIC BCG VACCINES SALES MARKET, BY END USER 2017-2025, ($MILLION)
TABLE 43. ASIA-PACIFIC BCG VACCINES SALES MARKET, BY COUNTRY, 2017-2025, ($MILLION)
TABLE 44. JAPAN BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 45. JAPAN VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 46. JAPAN VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 47. CHINA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 48. CHINA VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 49. CHINA BCG VACCINES SALES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 50. INDIA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 51. INDIA VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 52. INDIA VACCINES MARKET, BY END USER 2017-2025, ($MILLION)
TABLE 53. REST OF ASIA-PACIFIC BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 54. REST OF ASIA PACIFIC BCG VACCINES SALES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 55. LAMEA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 56. LAMEA BCG VACCINES MARKET, BY USAGE 2017-2025, ($MILLION)
TABLE 57. LAMEA BCG VACCINES SALES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 58. LAMEA BCG VACCINES SALES MARKET, BY COUNTRY, 2017-2025, ($MILLION)
TABLE 59. LATIN AMERICA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 60. LATIN AMERICA BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 61. LATIN AMERICA BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 62. MIDDLE EAST BCG VACCINES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 63. MIDDLE EAST BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 64. MIDDLE EAST BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 65. AFRICA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)
TABLE 66. AFRICA BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)
TABLE 67. AFRICA BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)
TABLE 68. AJ VACCINES: COMPANY SNAPSHOT
TABLE 69. AJ VACCINES: OPERATING SEGMENTS
TABLE 70. AJ VACCINES: PRODUCT PORTFOLIO
TABLE 71. SINOPHARM: COMPANY SNAPSHOT
TABLE 72. SINOPHARM: OPERATING SEGMENTS
TABLE 73. SINOPHARM: PRODUCT PORTFOLIO
TABLE 74. GSBPL: PRODUCT PORTFOLIO
TABLE 75. INTERVAX: COMPANY SNAPSHOT
TABLE 76. INTERVAX: PRODUCT PORTFOLIO
TABLE 77. JAPAN BCG LABORATORY: COMPANY SNAPSHOT
TABLE 78. JAPAN BCG LABORATORY: PRODUCT PORTFOLIO
TABLE 79. MERCK: COMPANY SNAPSHOT
TABLE 80. MERCK: OPERATING SEGMENTS
TABLE 81. MERCK: PRODUCT PORTFOLIO
TABLE 82. SANOFI: COMPANY SNAPSHOT
TABLE 83. SANOFI: OPERATING SEGMENTS
TABLE 84. SANOFI: PRODUCT PORTFOLIO
TABLE 85. SERUM: COMPANY SNAPSHOT
TABLE 86. SERUM: PRODUCT PORTFOLIO
TABLE 87. SSI: COMPANY SNAPSHOT
TABLE 88. SSI: OPERATING SEGMENTS
TABLE 89. SSI: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL BCG VACCINES SALES MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. DRIVERS, OPPORTUNITY, & CHALLENGE: GLOBAL BCG VACCINES SALES MARKET
FIGURE 04. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 05. MERCK: REVENUE SHARE BY PRODUCT, 2018 (%)
FIGURE 06. MERCK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 07. SANOFI: NET SALES, 2015–2017 ($MILLION)
FIGURE 08. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 09. SANOFI: REVENUE SHARE BY REGION, 2017 (%)
The adoption of BCG vaccine is anticipated to witness significant growth due to increase in cases of tuberculosis in the developing nations with inefficient healthcare support and facilities. Moreover, the BCG vaccines sales market has gained immense interest of the healthcare industry due to its high importance in eradicating one of the deadliest infectious diseases, i.e., tuberculosis, cause of mortality in majority of the developing countries. Asia is projected to register highest growth rate in the global BCG vaccines sales market due to massively increasing population, high prevalence of diseases, and growth in the healthcare market.
High prevalence of chronic diseases and increase in awareness for early disease diagnosis are the major factors that drive the market growth. BCG vaccines have gained popularity in developing countries, as it is the only vaccine available for TB and is on the World Health Organization’s (WHO) list of essential medicines. However, adverse effects of BCG vaccination in few patients are expected to restrain the market growth. Furthermore, global shortage of BCG vaccine is also expected to restrict the market growth. Currently, immune BCG is the largest segment of the global BCG vaccines sales market, in terms of revenue.
Download Sample
Purchase Full Report of
BCG Vaccines Sales Market
- Online Only
- $3456
- Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
- $3840
- Restricted to one authorized user
- One print only
- Available in Excel
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
- $5370
- Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
- $6450
- Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF - $8995
- Unlimited within company/enterprise
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Buy Full Version
"BCG Vaccines Sales Market"
Purchase Enquiry